Biotech stocks are a hot-button topic for retail investors on Stocktwits, where over four million users track these companies, hoping to spot the next big therapeutic breakthrough. Two names ...

Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a ...

Key 2024 Accomplishments Mainz Biomed and Thermo Fisher Scientific signed a collaboration agreement for the development of the Company’s next generation colorectal cancer (CRC) screening product ...

Mainz Biomed announced a follow-on offering of 2 million units, raising approximately $4 million for cancer detection initiatives.

Mainz Biomed begins the feasibility phase of its PancAlert project for non-invasive pancreatic cancer detection using blood samples.

View Mainz Biomed N.V. MYNZ stock quote prices, financial information, real-time forecasts, and company news from CNN.

Mainz Biomed is conducting a best-efforts public offering of up to 2.45M ordinary units and 2.49M pre-funded units. Each ordinary unit includes one ordinary share, one Class A warrant, and one ...

Mainz Biomed partners with Thermo Fisher to develop advanced colorectal cancer screening tools while enhancing ColoAlert for faster, accurate results.

Mainz Biomed published key findings from its groundbreaking eAArly DETECT study during a poster presentation at the renowned Digestive Disease Week (DDW) 2024 in Washington D.C.